4.6 Article

Acceleration of Bone Repair in NOD/SCID Mice by Human Monoosteophils, Novel LL-37-Activated Monocytes

Journal

PLOS ONE
Volume 8, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0067649

Keywords

-

Funding

  1. City of Hope

Ask authors/readers for more resources

Background: An incomplete understanding of bone forming cells during wound healing and ectopic calcification has led to a search for circulating cells that may fulfill this function. Previously, we showed that monoosteophils, a novel lineage of calcifying/bone-forming cells generated by treatment of monocytes with the natural peptide LL-37, are candidates. In this study, we have analyzed their gene expression profile and bone repair function. Methods and Findings: Human monoosteophils can be distinguished from monocytes, macrophages and osteoclasts by their unique up-regulation of integrin alpha 3 and down-regulation of CD14 and CD16. Monoosteophils express high mRNA and protein levels of SPP1 (osteopontin), GPNMB (osteoactivin), CHI3L1 (cartilage glycoprotein-39), CHIT1 (Chitinase 1), MMP-7, CCL22 and MAPK13 (p38MAPK delta). Monocytes from wild type, but not MAPK13 KO mice are also capable of monoosteophil differentiation, suggesting that MAPK13 regulates this process. When human monoosteophils were implanted in a freshly drilled hole in mid-diaphyseal femurs of NOD/SCID mice, significant bone repair required only 14 days compared to at least 24 days in control treated injuries. Conclusion: Human derived monoosteophils, characterized as CD45(+) alpha 3(+) alpha 3 beta(+) CD34(-) CD14(-)BAP (bone alkaline phosphatase)(-) cells, can function in an animal model of bone injury.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

SNPs in inflammatory genes CCL11, CCL4 and MEFV in a fibromyalgia family study

Zhifang Zhang, Jinong Feng, Allen Mao, Keith Le, Deirdre La Placa, Xiwei Wu, Jeffrey Longmate, Claudia Marek, R. Paul St Amand, Susan L. Neuhausen, John E. Shively

PLOS ONE (2018)

Article Immunology

CEACAM1 regulates the IL-6 mediated fever response to LPS through the RP105 receptor in murine monocytes

Zhifang Zhang, Deirdre La Placa, Tung Nguyen, Maciej Kujawski, Keith Le, Lin Li, John E. Shively

BMC IMMUNOLOGY (2019)

Article Cell Biology

STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

Chunyan Zhang, Chanyu Yue, Andreas Herrmann, Jieun Song, Colt Egelston, Tianyi Wang, Zhifang Zhang, Wenzhao Li, Heehyoung Lee, Maryam Aftabizadeh, Yi Jia Li, Peter P. Lee, Stephen Forman, George Somlo, Peiguo Chu, Laura Kruper, Joanne Mortimer, Dave S. B. Hoon, Wendong Huang, Saul Priceman, Hua Yu

CELL METABOLISM (2020)

Article Surgery

Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer

Yanghee Woo, Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Susanne G. Warner, Daniel Von Hoff, Yuman Fong

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2020)

Article Oncology

Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

Shyambabu Chaurasiya, Annie Yang, Seonah Kang, Jianming Lu, Sang-In Kim, Anthony K. Park, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Susanne G. Warner, Yuman Fong

ONCOIMMUNOLOGY (2020)

Article Oncology

Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity

Sang-In Kim, Anthony K. Park, Shyambabu Chaurasiya, Seonah Kang, Jianming Lu, Annie Yang, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Saul J. Priceman, Yuman Fong, Susanne G. Warner

Summary: The study found that CF33 oncolytic virus has good efficacy against colon cancer and can increase the infiltration of lymphocytes and macrophages in tumors. CF33 infection can upregulate PD-L1 expression on tumor cells and promote an increase in active CD8(+) T cells. Furthermore, combination treatment of CF33 derivatives with anti-PD-L1 resulted in durable tumor regression and long-term survival.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Biotechnology & Applied Microbiology

CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy

Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Susanne G. Warner, Yate-Ching Yuan, Zheng Liu, Haiyong Han, Daniel Von Hoff, Yuman Fong, Yanghee Woo

Summary: The study demonstrates that genetically modified oncolytic viruses can significantly upregulate PD-L1 expression in PDAC, and virus-delivered anti-PD-L1 antibodies can enhance anti-tumor immune killing in PDAC.

CANCER GENE THERAPY (2022)

Review Oncology

Toward comprehensive imaging of oncolytic viroimmunotherapy

Shyambabu Chaurasiya, Sang-In Kim, Michael O'Leary, Anthony K. Park, Jianming Lu, Seonah Kang, Zhifang Zhang, Annie Yang, Yanghee Woo, Yuman Fong, Susanne G. Warner

Summary: Oncolytic viruses infect and kill cancer cells, while activating immune cells against tumors. Real-time tracking of viral replication and immune responses is crucial for enhancing treatment effects. Additional modalities to track virus-induced changes in tumor microenvironments are being explored.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Article Oncology

Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer

Sang-In Kim, Shyambabu Chaurasiya, Venkatesh Sivanandam, Seonah Kang, Anthony K. Park, Jianming Lu, Annie Yang, Zhifang Zhang, Isabella A. Bagdasarian, Yanghee Woo, Joshua T. Morgan, Zhirong Yin, Yuman Fong, Susanne G. Warner

Summary: Pancreatic cancer resistance to immunotherapies is partly due to deficits in tumor-infiltrating immune cells and stromal density. Combination therapies that modify stroma and recruit immune cells are needed. This study found that using Calcipotriol to modify the stroma can enhance oncolytic viroimmunotherapy. The results showed that Calcipotriol decreases fibrosis, increases immune cell infiltration, and reduces T cell exhaustion.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Article Endocrinology & Metabolism

Role of lncRNA LIPE-AS1 in adipogenesis

Alyssa Thunen, Deirdre La Placa, Zhifang Zhang, John E. Shively

Summary: Recent studies have identified a long non-coding RNA, LIPE-AS1, that plays a potential regulatory role in adipogenesis. This study characterizes a specific isoform of the murine lncRNA, mLas-V3, which shows conservation in genomic organization and tissue expression between mouse and man. Knock down of mLas-V3 led to a decrease in pre-adipocyte cell differentiation and induced apoptosis, suggesting its role in protecting against stress associated with adipogenesis.

ADIPOCYTE (2022)

Article Medicine, Research & Experimental

A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer

Shyambabu Chaurasiya, Annie Yang, Zhifang Zhang, Jianming Lu, Hannah Valencia, Sang-In Kim, Yanghee Woo, Suanne G. Warner, Tove Olafsen, Yuqi Zhao, Xiwei Wu, Seymour Fein, Linda Cheng, Maria Cheng, Nicholas Ede, Yuman Fong

Summary: CF33-hNIS-anti-PD-L1, an oncolytic chimeric poxvirus encoding two transgenes, showed anti-tumor activity against triple-negative breast cancer models in mice. Preclinical toxicology studies demonstrated no adverse effects and a low risk of transmission. Stability and compatibility tests under clinical scenarios confirmed its suitability for clinical use.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Article Oncology

PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1

Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Sang-In Kim, Jianming Lu, Tove Olafsen, Susanne G. Warner, Yuman Fong, Yanghee Woo

Summary: CF33-hNIS-antiPDL1 has anti-pancreatic adenocarcinoma activity and can infect, detect, and kill peritoneal tumors.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Article Endocrinology & Metabolism

Reversal of obesity development in Ceacam1-/- male mice by bone marrow transplantation or introduction of the human CEACAM1 gene

Zhifang Zhang, Deirdre La Placa, Gabriel Gugiu, Alyssa Thunen, Keith Le, John E. Shively

Summary: Ceacam1 deficiency in mice leads to obesity and a higher risk of liver cancer. Bone marrow transplantation or introduction of the human CEACAM1 gene can reverse the obesity phenotype.

OBESITY (2022)

Article Oncology

Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K. Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo

Summary: CF33-OVs demonstrate effective antitumor activity and delivery of functional proteins in gastric cancer peritoneal metastases (GCPM) models when delivered intraperitoneally. These preclinical results will inform the design of future peritoneal-directed therapy in GCPM patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Endocrinology & Metabolism

CXCR2 specific endocytosis of immunomodulatory peptide LL-37 in human monocytes and formation of LL-37 positive large vesicles in differentiated monoosteophils

Zhifang Zhang, Keith Le, Deirdre La Placa, Brian Armstrong, Marcia M. Miller, John E. Shively

BONE REPORTS (2020)

No Data Available